A timeline of important Herceptin developments.
Paul Ehrlich, MD, wins the Nobel Prize for his idea that antibodies could be used like magic bullets to treat disease.
Georges Köhler, PhD, and César Milstein, PhD, uncover the technique for producing monoclonal antibodies. The pair win the Nobel Prize in physiology or medicine in 1984.
HER2 gene discovered.
Dennis Slamon, MD, PhD, and his colleagues publish data showing the link between HER2 overexpression and an aggressive type of breast cancer that affects 20 to 25 percent of the 213,000 women diagnosed with breast cancer each year.
Genentech scientists humanize an antibody directed at HER2 that comes to be known as Herceptin.
Phase I and II trials conducted.
Phase III trials for Herceptin completed. Results show that Herceptin in combination with chemotherapy slows the progression of cancer and increases tumor shrinkage in metastatic disease.
Development begins for a diagnostic kit to screen breast cancer patients for HER2 overexpression.
Genentech submits application for FDA approval of Herceptin.
Phase III trials initiated to evaluate Herceptin in the adjuvant setting for breast cancer.
Data from a phase III trial is published in The New England Journal of Medicine that shows a 25 percent increase in survival rate for women with HER2-positive metastatic breast cancer who receive Herceptin and chemotherapy compared with chemotherapy alone.
FDA approves use of FISH (fluorescent in situ hybridization) gene amplification test for HER2 gene.
Data from three large trials of Herceptin used in the adjuvant setting, presented at the annual meeting of the American Society of Clinical Oncology, show the drug reduces the risk of recurrence by 50 percent in HER2-positive breast cancer patients.
Genentech submits application to the FDA for approval of Herceptin with chemotherapy in early-stage HER2-positive breast cancer in the adjuvant setting.